U.S. Acromegaly Drugs Market is Growing with a 6.4% of CAGR in the Forecast Period of 2020 to 2027

U.S. Acromegaly Drugs Market is growing with the factors such as high prevalence of acromegaly. Increasing prevalence of hormonal diseases, endocrine diseases and hypopituitarism also acts as a major factor for the growth of the market. Rising R&D expenditure as well as growing awareness about acromegaly has also given a boom to the U.S. acromegaly drugs market.

Growing number of dental clinics has propelled the demand of the market. While high costs of the drugs have reduced the demand of the acromegaly drugs.

U.S. Acromegaly Drugs Market Scenario                                 

According to Data Bridge Market Research, the market for acromegaly drugs in the U.S. is growing with market leader such as Ipsen Pharma which accounts an estimated market share of approximately 35.87%. The company has gained revenue by geographical expansion across the globe. For instance, in June 2018, Ipsen Pharma announced that, company will establish its North American headquarters in Cambridge. Owing to this, company anticipated create a fully integrated biopharmaceutical business in the U.S. Resulting it will boost company growth in the coming years.

U.S. Acromegaly Drugs MarketTrends Impacting the Market  

The U.S. acromegaly treatment market is becoming more competitive every year with companies such as Ipsen Pharma, Novartis AG, Pfizer Inc. which are the market leaders for acromegaly drugs market. The data bridge market research new reports highlight the major growth factors and opportunities in the U.S. acromegaly drugs market.         

For more analysis on the U.S. acromegaly drugs market request for a briefing with our analysts

New Market Developments

  • In January 2020, Novartis AG announced the acquisition of the Medicines Company through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation. This acquisition has provided unique opportunity to expand the presence of Novartis AG’s products across the world.

Scope of U.S. Acromegaly Drugs Market 

All country based analysis of the U.S. acromegaly drugs market is further analysed based on maximum granularity into further segmentation. On the basis of disease type, the U.S. acromegaly drugs market is segmented into ectopic acromegaly and pseudoacromegaly. On the basis of drugs class, the U.S. acromegaly drugs market is segmented into somatostatin analogues, growth hormone receptor antagonists and dopamine agonists. On the basis of drugs type, the U.S. acromegaly drugs market is segmented into branded and generics. On the basis of route of administration, the U.S. acromegaly drugs market is segmented into parenteral and oral. On the basis of end user, the U.S. acromegaly drugs market is segmented into hospitals, specialty clinics, homecare and others. On the basis of distribution channel, the U.S. acromegaly drugs market is segmented into hospitals pharmacy, retail pharmacy and online pharmacy.

To know more about the study

Key Pointers Covered in the U.S. Acromegaly Drugs Market Industry Trends and Forecast to 2027

  • Market Size
  • Top to Bottom Market Analysis
  • Recent Developments for Market Competitors
  • Recent Market Value for Different Countries
  • Market value and over view of acromegaly drugs  market
  • Company profiling of top eight players of acromegaly drugs market

Key Market Competitors Covered in the Report

  • Novartis AG
  • Mylan N.V.
  • Ipsen Pharma
  • Pfizer Inc.
  • Fresenius Kabi USA (A Subsidiary of Fresenius Kabi AG)
  • Zydus Pharmaceuticals Inc. (A Subsidiary of Zydus Cadila)
  • Par Pharmaceuticals (A Subsidiary of Endo International plc)
  • Hikma Pharmaceuticals PLC
  • Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.)
  • Chiasma, Inc.
  • Ingenus Pharmaceuticals, LLC
  • Recordati Rare Diseases (A Subsidiary of RECORDATI S.p.A.)
  • Sun Pharmaceutical Industries Ltd.
  • Sagent Pharmaceuticals, Inc. (A Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.)

Above are the key players covered in the report, to know about more and exhaustive list of U.S. acromegaly drugs companies’, contact us

Research Methodology: U.S. Acromegaly Drugs Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

  • Demand Side: Doctors, Healthcare Professionals
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Related Reports

Browse in Healthcare Category Related Reports@